BAGSVAERD, Denmark—Novo Holdings, the Danish drugmaker’s controlling shareholder, said it acquired New Jersey-based Catalent Inc. in a deal that values the contract manufacturer at $16.5 billion. Novo Nordisk, in turn, said it will acquire three manufacturing sites from Novo Holdings for $11 billion.
The acquisition comes days after Novo executives said they had boosted Wegovy supplies enough to offer more starting doses to new patients, after curtailing such doses last year to ensure there would be enough for existing patients. The anti-obesity drug has been so popular that Novo hasn’t been able to churn out enough, leading the U.S. Food and Drug Administration to designate it in short supply.